keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/29229936/identification-of-a-gene-signature-for-discriminating-metastatic-from-primary-melanoma-using-a-molecular-interaction-network-approach
#1
Rahul Metri, Abhilash Mohan, Jérémie Nsengimana, Joanna Pozniak, Carmen Molina-Paris, Julia Newton-Bishop, David Bishop, Nagasuma Chandra
Understanding the biological factors that are characteristic of metastasis in melanoma remains a key approach to improving treatment. In this study, we seek to identify a gene signature of metastatic melanoma. We configured a new network-based computational pipeline, combined with a machine learning method, to mine publicly available transcriptomic data from melanoma patient samples. Our method is unbiased and scans a genome-wide protein-protein interaction network using a novel formulation for network scoring...
December 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29228646/discordance-of-pathological-thin-melanoma-thickness-and-t-stage-in-seer-registry-impacts-on-clinical-management-and-research-directions
#2
Zhichao Wang, Haizhou Li, Xinyang Liu, Jinhong Bae, Xin Huang, Yashan Gao, Xiangwen Xu, Jihan Guo, Lin Lu, Tao Zan, Qingfeng Li
Background: Ultrathin melanoma was previously demonstrated to have higher risk for melanoma-specific mortality using SEER database. However, these guideline-changing conclusions has been recently challenged by miscoding of thickness. This present study was performed to assess the prognosis of thin and ultrathin melanoma using only surgically-treated, pathologically confirmed and after removal of discordant cases. Methods: Melanoma patients from SEER database who were initially diagnosed with histologically confirmed and surgically treated melanoma from 1998 to 2012 were included...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29215399/hemorrhage-of-liver-and-bone-metastases-as-a-result-of-rapid-response-to-dual-braf-mek-inhibition-in-metastatic-melanoma-a-case-report
#3
Tine Loyson, Emilie Werbrouck, Kevin Punie, Lawrence Bonne, Vincent Vandecaveye, Oliver Bechter
Combination therapy using a BRAF and MEK inhibitor significantly improves both progression-free and overall survival in patients with BRAF V600-mutated stage IV melanoma. Dual MAPK inhibition achieves an objective response in the majority of patients. We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases. The patient commenced dabrafenib and trametinib with clinical and biochemical signs of response after 2 days. On day 3 she developed grade 3 liver hemorrhage, which was successfully embolized...
December 5, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29204166/patterns-of-care-and-survival-outcomes-after-treatment-for-uveal-melanoma-in-the-post-coms-era-2004-2013-a-surveillance-epidemiology-and-end-results-analysis
#4
Yuan James Rao, Julia Sein, Shahed Badiyan, Julie K Schwarz, Todd DeWees, Perry Grigsby, Prabakar Kumar Rao
Purpose: The Collaborative Ocular Melanoma Study (COMS) established modern treatment recommendations for uveal melanoma. We aim to evaluate patterns of care and survival outcomes in the time after COMS. Material and methods: The retrospective study population includes 2,611 patients in the SEER database treated for uveal melanoma between 2004-2013. Patients stage were T1-4N0M0. Data analyzed included age, clinical stage, tumor size, race, and treatment. Treatments included enucleation (EN) and globe preserving therapy (GPT), which consisted of limited surgical resection or ablation (LSRA), external beam radiation (EBRT), or brachytherapy (BT)...
October 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29202855/soluble-cd73-as-biomarker-in-patients-with-metastatic-melanoma-patients-treated-with-nivolumab
#5
Silvana Morello, Mariaelena Capone, Claudia Sorrentino, Diana Giannarelli, Gabriele Madonna, Domenico Mallardo, Antonio M Grimaldi, Aldo Pinto, Paolo Antonio Ascierto
BACKGROUND: Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. METHODS: In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma stage IV and its correlation with the response to nivolumab. The soluble CD73 (sCD73) enzyme activity was measured in the serum of 37 melanoma patients before receiving nivolumab and the Harrel's C index was used to find the best cut-off for this biomarker...
December 4, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29198779/mitotic-rate-is-associated-with-positive-lymph-nodes-in-thin-melanomas
#6
Lee Wheless, Chelsea A Isom, Mary A Hooks, Rondi M Kauffmann
BACKGROUND: The American Joint Commission on Cancer will remove mitotic rate from its staging guidelines in 2018. OBJECTIVE: Using a large nationally-representative cohort, we examined the association between mitotic rate and lymph node positivity among thin melanomas. METHODS: 149,273 thin melanomas in the National Cancer Database were examined for their association between high-risk features of mitotic rate, ulceration, and Breslow depth, with lymph node status...
November 30, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29194673/transected-thin-melanoma-implications-for-sentinel-lymph-node-staging
#7
Garth Herbert, Giorgos C Karakousis, Edmund K Bartlett, Salman Zaheer, Danielle Graham, Brian J Czerniecki, Douglas L Fraker, Charlotte Ariyan, Daniel G Coit, Mary S Brady
BACKGROUND AND OBJECTIVES: Indications for sentinel lymph node (SLN) biopsy in patients with thin melanoma (≤1 mm thick) are controversial. We asked whether deep margin (DM) positivity at initial biopsy of thin melanoma is associated with SLN positivity. METHODS: Cases were identified using prospectively maintained databases at two melanoma centers. Patients who had undergone SLN biopsy for melanoma ≤1 mm were included. DM status was assessed for association with SLN metastasis in univariate and multivariate analyses...
November 30, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29188268/sensitivity-of-preference-based-quality-of-life-measures-for-economic-evaluations-in-early-stage-melanoma
#8
Mbathio Dieng, Nadine A Kasparian, Anne E Cust, Daniel S J Costa, Anh Tran, Phyllis N Butow, Scott W Menzies, Graham J Mann, Rachael L Morton
Importance: The diagnosis of a life-threatening disease like melanoma can affect all aspects of a person's life, including health-related quality of life (HRQOL) and psychological aspects of melanoma such as fear of cancer recurrence (FCR). Economic evaluations of psychological interventions require preference-based (utility) instruments that are sensitive to changes in well-being and HRQOL; however, very few studies have evaluated the sensitivity of these instruments when used for people with melanoma...
November 29, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/29177235/metastatic-melanoma-patients-sensitivity-to-ipilimumab-cannot-be-predicted-by-tumor-characteristics
#9
Kara Rossfeld, Erinn M Hade, Alexandra Gangi, Matthew Perez, Emily N Kinsey, Joanna Grabska, Ashley Ederle, Jonathan Zager, April K Salama, Thomas E Olencki, Georgia M Beasley
Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and toxicities can be severe leaving need for reliable clinical predictive markers. Methods: We examined primary tumor characteristics including ulceration, BRAF mutation status, and Breslow depth in patients who subsequently developed stage IV disease and were treated with ipilimumab at 3 institutions. Patients in this study were not treated on clinical trials...
October 2017: International Journal of Surgery. Oncology
https://www.readbyqxmd.com/read/29176501/phase-iiib-safety-results-from-an-expanded-access-protocol-of-talimogene-laherparepvec-for-patients-with-unresected-stage-iiib-ivm1c-melanoma
#10
Jason Chesney, Sanjay Awasthi, Brendan Curti, Laura Hutchins, Gerald Linette, Pierre Triozzi, Marcus C B Tan, Russell E Brown, John Nemunaitis, Eric Whitman, Christopher Windham, Jose Lutzky, Gerald F Downey, Nicolas Batty, Thomas Amatruda
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We aim to describe the safety of talimogene laherparepvec. Intralesional talimogene laherparepvec was administered at less than or equal to 4 ml×10 PFU/ml at protocol day 1, then less than or equal to 4 ml×10 PFU/ml 21 days later, and then every 14 days. Treatment continued until complete response, absence of injectable tumors, progressive disease, intolerance, or US Food and Drug Administration approval...
November 22, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29163685/expression-of-cancer-testis-antigens-mage-a-mage-c1-gage-and-ctag1b-in-benign-and-malignant-thyroid-diseases
#11
Daniel Hardy Melo, Rui Celso Martins Mamede, Luciano Neder, Wilson Araújo Silva, Mateus Camargo Barros-Filho, Luiz Paulo Kowalski, Clóvis Antonio Lopes Pinto, Marco Antônio Zago, David Livingstone Alves Figueiredo, Achim A Jungbluth
Despite considerable advances in the understanding of thyroid gland biology, correctly diagnosing thyroid nodules and treating high-grade thyroid carcinoma remains challenging. Cancer/testis (CT) antigens have emerged as potential diagnostic tools as well as targets of potential cancer vaccinations. In the present study, a total of 117 patients who underwent surgical therapy for thyroid disease were available for analysis. The expression levels of melanoma-associated antigen (MAGE) A, MAGE-C1/CT7, cancer/testis antigen 1B (CTAG1B) and G antigen (GAGE) were analyzed by immunohistochemistry...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29156734/pax3d-mrna-over-2-76-copies-%C3%A2%C2%B5l-in-the-bloodstream-predicts-cutaneous-malignant-melanoma-relapse
#12
Chiara Autilio, Carmela Paolillo, Maria Michela Lavieri, Krizia Pocino, Elisa De Paolis, Enrico Di Stasio, Paolo Marchetti, Cappellini Antonini Gian Carlo, Ettore Capoluongo
Objective: The aim of this study was to evaluate if our molecular algorithm, based on tumor circulating transcripts, may predict relapse risk in cutaneous malignant melanoma (CMM). Results: The multi-marker panel was able to differentiate patients with CMM from HC with high diagnostic sensitivity and specificity, especially for MITF-m and TGFB2 (91-100%) whose levels decreased during follow-up of recurrence-free patients, and remained stable in the case of relapse...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156467/-diagnosis-and-therapy-of-iris-lesions
#13
Joel M Mor, Konrad R Koch, Ludwig M Heindl
The most common iris lesions are iris nevi, iris melanomas and iris pigment epithelium cysts. However, there is an abundance of rare differential diagnoses that have to be considered, including other melanocytic and non-melanocytic lesions. Diagnostic tools include the slit lamp examination, gonioscopy, tonometry, transillumination, ultrasound biomicroscopy (UBM), optical coherence tomography, fluorescein angiography and standardized photography-assisted documentation. The timely identification of malignant lesions (i...
November 20, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29136692/-expression-and-prognostic-values-of-pd-1-pd-l1-and-ido-1-in-sinonasal-malignant-mucosal-melanoma
#14
H Q Liu, B Q Zou, S Y Wang
Objective: To investigate the correlation between the expression of programmed death-1(PD-1), PD ligand-1(PD-L1), indoleamine 2, 3-dioxygenase 1(IDO-1) and clinical parameters in sinonasal malignant mucosal melanoma (SNM). Methods: Samples from 86 SNM patients who did not receive immune-targeted therapy and radio-chemotherapy were analyzed for PD-1, PD-L1, and IDO-1 expression by immunohistochemistry. Results: High clinical/pathologic staging, brain metastases and advanced age were independent risk factors of poor prognosis...
November 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29136453/randomized-phase-iii-trial-of-adjuvant-therapy-with-locoregional-interferon-beta-versus-surgery-alone-in-stage-ii-iii-cutaneous-melanoma-japan-clinical-oncology-group-study-jcog1309-j-feron
#15
Kenjiro Namikawa, Arata Tsutsumida, Tomonori Mizutani, Taro Shibata, Tatsuya Takenouchi, Shusuke Yoshikawa, Yoshio Kiyohara, Hiroshi Uchi, Masutaka Furue, Dai Ogata, Tetsuya Tsuchida, Naoya Yamazaki
The Dermatologic Oncology Group of Japan Clinical Oncology Group has started a randomized phase III trial to confirm the superiority of adjuvant therapy with locoregional interferon beta in overall survival over surgery alone for patients with pathological stage II/III cutaneous melanoma (JCOG1309). Patients in the interferon beta arm receive intra- or subcutaneous injections of interferon beta directly into the surgical site at a flat dose of 3 million units once per day. Treatment is repeated for 10 consecutive days every 8 weeks for a total of 3 courses during the induction phase, then 1-day injection every 4 weeks for 2...
July 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29132694/unrelated-immunodeficiency-states-may-impact-outcomes-and-immune-checkpoint-molecule-expression-in-patients-with-mycosis-fungoides-a-clinicopathologic-case-control-study
#16
Shay Warren, Meenal Kheterpal, Patricia L Myskowski, Alison Moskowitz, Steven M Horwitz, Melissa P Pulitzer
BACKGROUND: Immunodeficiency (ID) correlates with worse outcomes and decreased immune checkpoint molecule expression in melanoma. The impact of ID in mycosis fungoides (MF) is unknown. OBJECTIVE: Our goal was to evaluate the impact of ID in MF. METHODS: We conducted a case-control study of 17 patients with MF and ID versus age-, stage-, and race-matched controls as a subset of a comparative analysis of 23 patients with MF with ID (prior lymphoma, recent/current pregnancy, HIV, hypogammaglobulinemia, and prior chemotherapy) versus without ID...
November 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29123256/favourable-prognostic-role-of-histological-regression-in-stage-iii-positive-sentinel-lymph-node-melanoma-patients
#17
D Zugna, R Senetta, S Osella-Abate, M T Fierro, A Pisacane, A Zaccagna, A Sapino, V Bataille, A Maurichi, F Picciotto, P Cassoni, P Quaglino, S Ribero
BACKGROUND: Sentinel lymph node (SLN)-positive melanoma patients are a heterogeneous group of patients with survival rates ranging from ∼20 to over 80%. No data are reported concerning the role of histological regression on survival in stage III melanoma. METHODS: The study included 365 patients with positive SLN from two distinct hospitals. The model was developed on patients from 'AOU Città della Salute e della Scienza di Torino', and externally validated on patients from IRCCS of Candiolo...
November 9, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29122287/radiologic-and-histopathologic-correlation-of-different-growth-patterns-of-metastatic-uveal-melanoma-to-the-liver
#18
Albert Liao, Pardeep Mittal, David H Lawson, Jenny J Yang, Eszter Szalai, Hans E Grossniklaus
PURPOSE: The purpose of this study was to correlate magnetic resonance imaging (MRI) radiographic results with histopathologic growth patterns of metastatic uveal melanoma (UM) to the liver. DESIGN: Clinicopathologic correlation. PARTICIPANTS: Patients with metastatic UM to the liver. METHODS: A retrospective review of MRI images of patients with metastatic UM to the liver at a single institution between 2004 and 2016 was performed...
November 6, 2017: Ophthalmology
https://www.readbyqxmd.com/read/29112704/circulating-tumor-dna-predicts-survival-in-patients-with-resected-high-risk-stage-ii-iii-melanoma
#19
R J Lee, G Gremel, A Marshall, K A Myers, N Fisher, J Dunn, N Dhomen, P G Corrie, M R Middleton, P Lorigan, R Marais
Background: Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma. Patients and methods: We performed droplet digital polymerase chain reaction to detect BRAF and NRAS mutations in plasma taken after surgery from 161 stage II/III high-risk melanoma patients enrolled in the AVAST-M adjuvant trial...
November 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29107860/site-of-childhood-cancer-care-in-the-netherlands
#20
A M J Reedijk, M van der Heiden-van der Loo, O Visser, H E Karim-Kos, J A Lieverst, J G de Ridder-Sluiter, J W W Coebergh, L C Kremer, R Pieters
BACKGROUND: Due to the complexity of diagnosis and treatment, care for children and young adolescents with cancer preferably occurs in specialised paediatric oncology centres with potentially better cure rates and minimal late effects. This study assessed where children with cancer in the Netherlands were treated since 2004. METHODS: All patients aged under 18 diagnosed with cancer between 2004 and 2013 were selected from the Netherlands Cancer Registry (NCR) and linked with the Dutch Childhood Oncology Group (DCOG) database...
November 3, 2017: European Journal of Cancer
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"